Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Kathrine T. Isaksen, MD, Klaus Beiske, MD PhD, Erlend B. Smeland, MD PhD, Judit Jørgensen, MD PhD, Marianne Brodtkorb, MD PhD, June Helen Myklebust, PhD, Mats Jerkeman, MD Professor, Leo Meriranta, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD PhD, David W. Scott, MBChB, PhD, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD

Blood (2019) 134 (Supplement_1): 1485.

https://doi.org/10.1182/blood-2019-121467

Published: 2019

Journal Articles

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Jari Haukka, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 2781.

https://doi.org/10.1182/blood-2019-131220

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Matias Autio, Suvi-Katri Leivonen, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Teijo Pellinen, PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5230.

https://doi.org/10.1182/blood-2019-129681

Published: 2019

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

Leo Meriranta, MS, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sandeep Dave, MD, Sirpa Leppa, MD Prof

Blood (2018) 132 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2018-99-117958

Published: 2018

Journal Articles

Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

Sirpa Leppa, MD Prof, Judit Jørgensen, MD PhD, Leo Meriranta, MS, Klaus Beiske, MD PhD, Jan M.A. Delabie, MD PhD, Elisabeth Ralfkiaer, MD DMSC, Signe Spetalen, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Harald Holte, MD PhD

Blood (2018) 132 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2018-99-120057

Published: 2018

Journal Articles

Impact of Rituximab and Methotrexate on the Survival of the Patients with Sinonasal Tract Diffuse Large B-Cell Lymphoma

Pauli Vähämurto, MD, Susanna Mannisto, Marjukka Pollari, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Antti A. Mäkitie, MD PhD, Sirpa Leppä, MD PhD

Blood (2016) 128 (22): 1859.

https://doi.org/10.1182/blood.V128.22.1859.1859

Published: 2016

Journal Articles

Characterization of the Microrna Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing

Suvi-Katri Leivonen, PhD, Katherine Icay, MSc, Chengyu Liu, MSc, Minna Taskinen, PhD, Rainer Lehtonen, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Jan Delabie, MD PhD, Harald Holte, MD PhD, Sampsa Hautaniemi, PhD, Sirpa Leppä, MD PhD

Blood (2014) 124 (21): 1626.

https://doi.org/10.1182/blood.V124.21.1626.1626

Published: 2014

Journal Articles

Somatic Mutations in E3 Ubiquitin Ligase Deltex 1 Are Associated with Survival in Diffuse Large B-Cell Lymphoma

Minna Taskinen, PhD, Leo Meriranta, BM, Annika Pasanen, MD PhD, Riku Louhimo, MSc, Alejandra Cervera, MSc, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Harald Holte, MD PhD, Jan Delabie, MD PhD, Rainer Lehtonen, PhD, Sampsa Hautaniemi, PhD, Sirpa Leppä

Blood (2014) 124 (21): 1688.

https://doi.org/10.1182/blood.V124.21.1688.1688

Published: 2014

Journal Articles

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Riikka Räty, Tuomo Honkanen, Esa Jantunen, MDPhD, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Outi Kuittinen, Minna Lehto, Maija Mikkola, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, MD, Sanna Siitonen, Merja Suominen, MD, Mirja Vapaatalo, Erkki Elonen

Blood (2014) 124 (21): 1749.

https://doi.org/10.1182/blood.V124.21.1749.1749

Published: 2014

Journal Articles

Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma

Minna Taskinen, PhD, Ping Chen, MSc, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Alejandra Cervera, MSc, Jan Delabie, Harald Holte, MD, PhD, Sampsa Hautaniemi, Sirpa Leppä

Blood (2013) 122 (21): 75.

https://doi.org/10.1182/blood.V122.21.75.75

Published: 2013

Journal Articles

Alternative Splicing and Expression of Class II Tubulin Beta ( TUBB2B ) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

Minna Taskinen, PhD, Satu Koivula, MSc, Ping Chen, MSc, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Alejandra Cervera, MSc student, Jan Delabie, Harald Holte, Jr., MD, PhD, Sampsa Hautaniemi, Sirpa Leppä

Blood (2012) 120 (21): 1557.

https://doi.org/10.1182/blood.V120.21.1557.1557

Published: 2012

Journal Articles

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Blood (2012) 120 (21): 747.

https://doi.org/10.1182/blood.V120.21.747.747

Published: 2012

Journal Articles

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

Harald Holte, MD, PhD, Sirpa M. Leppa, MD, PhD, Magnus Bjorkholm, MD, PhD, Oystein Fluge, MD, PhD, Sirkku Jyrkkio, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fossa, MD, PhD, Björn Östenstad, MD, PhD, Eva Lofvenberg, MD, PhD, Marie Nordström, MD, PhD, Lars Möller-Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2008) 112 (11): 3604.

https://doi.org/10.1182/blood.V112.11.3604.3604

Published: 2008

Journal Articles

STAT5 Signaling Is Associated with the Outcome of Follicular and Mantle Cell Lymphoma Patients Treated with Immunochemotherapy.

Sirpa Leppä, MD, PhD, Minna Taskinen, MSci, Antti Sommarhem, MD, Erkki Elonen, MD, PhD, Matti Nykter, PhD, Outi Monni, PhD, Tuomo Timonen, MD, PhD, Sampsa Hautaniemi, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD, Seppo Meri, MD, PhD

Blood (2007) 110 (11): 2626.

https://doi.org/10.1182/blood.V110.11.2626.2626

Published: 2007

Journal Articles

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Blood (2007) 110 (11): LB1.

https://doi.org/10.1182/blood.V110.11.LB1.lb1

Published: 2007

Journal Articles

Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged Follow-Up of 86 Patients Treated with BEAM/BEAC + PBSCT Confirms That Addition of High-Dose Ara-C and Rituximab to CHOP Induction + In-Vivo Purging with Rituximab Increases Clinical and Molecular Response Rates, PCR-Neg. Grafts, Failure-Free, Relapse-Free and Overall Survival.

Christian H. Geisler, MD, PhD, Erkki Elonen, MD, PhD, Arne Kolstad, MD, PhD, Anna Laurell, MD, PhD, Niels S. Andersen, MD, PhD, Lone B. Pedersen, Mats Jerkeman, MD, PhD, Marie Nordstroem, MD, PhD, Grete F. Lauritzen, MD, PhD, Elisabeth Ralfkiaer, MD, PhD, Maans Aakerman, MD, PhD, Christer Sundstroem, MD, PhD, Ruth Langholm, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, MD, PhD

Blood (2004) 104 (11): 8.

https://doi.org/10.1182/blood.V104.11.8.8

Published: 2004

NARROW

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

Impact of Rituximab and Methotrexate on the Survival of the Patients with Sinonasal Tract Diffuse Large B-Cell Lymphoma

Characterization of the Microrna Expression Profiles of Paired Primary and Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) By Next-Generation Sequencing

Somatic Mutations in E3 Ubiquitin Ligase Deltex 1 Are Associated with Survival in Diffuse Large B-Cell Lymphoma

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Global Profiling Of Outcome Associated Alternative Splicing Events and Gene Expression In Diffuse Large B-Cell Lymphoma

Alternative Splicing and Expression of Class II Tubulin Beta ( TUBB2B ) Are Associated with Outcome in Diffuse Large B-Cell Lymphoma

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2–3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years

STAT5 Signaling Is Associated with the Outcome of Follicular and Mantle Cell Lymphoma Patients Treated with Immunochemotherapy.

Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only